<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101124171</journal-id>
<journal-id journal-id-type="nlm-ta">Nat Rev Drug Discov</journal-id>
<journal-id journal-id-type="iso-abbrev">Nat Rev Drug Discov</journal-id>
<journal-title-group>
<journal-title>Nature reviews. Drug discovery</journal-title>
</journal-title-group>
<issn pub-type="ppub">1474-1776</issn>
<issn pub-type="epub">1474-1784</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29075003</article-id>
<article-id pub-id-type="pmc">6882681</article-id>
<article-id pub-id-type="manuscript">EMS84996</article-id>
<article-id pub-id-type="doi">10.1038/nrd.2017.178</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Trends in GPCR drug discovery: new agents, targets and
indications</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hauser</surname>
<given-names>Alexander S.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Attwood</surname>
<given-names>Misty M.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rask-Andersen</surname>
<given-names>Mathias</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schiöth</surname>
<given-names>Helgi B.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gloriam</surname>
<given-names>David E.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Drug Design and Pharmacology, Faculty of Health and
Medical Sciences, University of Copenhagen, Copenhagen, Denmark</aff>
<aff id="A2">
<label>2</label>Department of Neuroscience, Functional Pharmacology, University of
Uppsala, Uppsala, Sweden</aff>
<aff id="A3">
<label>3</label>Department of Immunology, Genetics and Pathology, Science for Life
Laboratory, University of Uppsala, Uppsala, Sweden</aff>
<author-notes>
<corresp id="CR1">Correspondence to <email>david.gloriam@sund.ku.dk</email>, tel.:
+45 93 56 54 49</corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P51">
<bold>Competing interest statement</bold>
</p>
<p id="P52">The authors declare no competing interests.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>01</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>27</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="nihms-submitted">
<day>20</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>28</day>
<month>11</month>
<year>2019</year>
</pub-date>
<volume>16</volume>
<issue>12</issue>
<fpage>829</fpage>
<lpage>842</lpage>
<!--elocation-id from pubmed: 10.1038/nrd.2017.178-->
<abstract>
<p id="P1">G protein-coupled receptors (GPCRs) are the most intensively studied drug
targets, largely due to their substantial involvement in human pathophysiology
and their pharmacological tractability. Here, we report the first analysis of
all GPCR drugs and agents in clinical trials. This reveals the current trends
across molecule types, drug targets and therapeutic indications, including
showing that 481 drugs (~34% of all drugs approved by the FDA) act at 107
unique GPCR targets. Approximately 320 agents are currently in clinical trials,
of which ~36% target 64 potentially novel GPCR targets without an
approved drug, and the number of biological drugs, allosteric modulators and
biased agonists has grown. The major disease indications for GPCR modulators
show a shift towards diabetes, obesity, and Alzheimer’s disease, while
other central nervous system disorders remain highly represented. The 227 (57%)
non-olfactory GPCRs that are yet to be explored in clinical trials have broad
untapped therapeutic potential, particularly in genetic and immune system
disorders. Finally, we provide an interactive online resource to analyse and
infer trends in GPCR drug discovery.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>